

Abstract

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal
5 former; wherein the API has at least one functional group selected from ether, thioether,
alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate
ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid,
sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp²
amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic
10 ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide,
peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least
one functional group selected from amine, amide, pyridine, imidazole, indole,
pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and
methyl thio, such that the API and co-crystal former are capable of co-crystallizing from
15 a solution phase under crystallization conditions.